ERBB2 and inflammatory breast carcinoma: Patients with MPD and underlying invasive breast carcinoma (IBC) experience significantly worse survival compared to those with IBC alone, driven by higher lymph node involvement, reduced hormone receptor expression, and elevated HER2 positivity.